RSV Shot for Infants: CDC Panel & RFK Jr. Reaction
- A government advisory panel endorsed Merck's Enflonsia shot Thursday for infants, a decision seen as a victory for public health officials amid ongoing debates about immunization strategies.
- The approval of Enflonsia offers reassurance to drugmakers and the medical community,particularly after recent changes to the advisory panel. The infant RSV immunization is now positioned to compete...
- Both Enflonsia and Beyfortus are monoclonal antibodies that provide immediate protection, though they target different parts of the virus.
The CDC advisory panel has recommended Merck’s Enflonsia for infants, marking a pivotal moment in protecting newborns from the infant RSV virus. This decision, ensuring broad insurance coverage, arises amidst ongoing public health discussions about immunization. The Merck RSV shot aims too compete with existing solutions. Key details include the shot’s potential to significantly reduce hospitalizations and the dissenting votes from panel members raising safety questions about the respiratory syncytial virus shot. news Directory 3 provides up-to-the-minute coverage on this and related health developments. Learn the impact of this endorsement and it’s implications for the upcoming RSV season. Discover what’s next …
Merck RSV Shot Wins Key Endorsement for Infant Use
A government advisory panel endorsed Merck’s Enflonsia shot Thursday for infants, a decision seen as a victory for public health officials amid ongoing debates about immunization strategies. The Advisory Commitee on Immunization Practices (ACIP) voted to include the Merck RSV shot on the list of recommended childhood immunizations, ensuring broad insurance coverage.
The approval of Enflonsia offers reassurance to drugmakers and the medical community,particularly after recent changes to the advisory panel. The infant RSV immunization is now positioned to compete with Sanofi and AstraZeneca’s Beyfortus as the RSV season approaches.
Both Enflonsia and Beyfortus are monoclonal antibodies that provide immediate protection, though they target different parts of the virus.
Dr. Richard M. Haupt, head of global medical affairs at Merck, stated that the recommendations are a critical step in reducing the burden of RSV on infants and families.
RSV leads to thousands of deaths among older adults and hundreds of infant deaths annually. Complications from the virus are a primary cause of newborn hospitalizations. Clinical trials showed Enflonsia reduced RSV-related hospitalizations by more than 84% and lower respiratory infection hospitalizations by 90% in infants up to five months old, compared to a placebo.
Retsef Levi and Vicky Pebsworth, two members of the panel known for their skepticism about vaccines, voted against the recommendation, raising concerns about the respiratory syncytial virus shot’s safety.